Merck KGaA, Darmstadt, Germany, will leverage Biolojic Design’s AI capabilities to create potential best-in-class multi-specific antibodies that uniquely modulate biology.
Sidley represented Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, in a multi-target drug discovery collaboration with Merck KGaA, Darmstadt, Germany. The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.
Under the terms of the agreement, Biolojic Design will receive a low double-digit million euro upfront payment and research funding from Merck KGaA, Darmstadt, Germany, and be eligible for drug discovery, development, regulatory, and commercial milestone payments that may total up to €346 million. Biolojic Design will also be eligible to receive tiered royalties on net product sales.
The team was led by Asher M. Rubin and Cassidy A. Pomeroy-Carter (Technology and Life Sciences Transactions); and included Olivier Goarnisson and Eva von Mühlenen (Food, Drug and Medical Device).
For additional information, please refer to the press release.
